Nalmefene: A review of its use in the treatment of alcohol dependence

CNS Drugs

Volumn 27, Issue 9, 2013, Pages 761-772

  Keating, Gillian M ^a  

^a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; DICLOFENAC; DISULFIRAM; FLUCONAZOLE; MECLOFENAMIC ACID; MEDROXYPROGESTERONE; NALMEFENE; PLACEBO;

ALCOHOL CONSUMPTION; ALCOHOLISM; AREA UNDER THE CURVE; DIZZINESS; DRINKING BEHAVIOR; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SINGLE DRUG DOSE; TABLET;

ALCOHOL DRINKING; ALCOHOLISM; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; HUMANS; INTERNATIONALITY; NALTREXONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84883227589     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0101-y     Document Type: Review

References (62)

1. Rehm J. The risks associated with alcohol use and alcoholism. Alcohol Res Health. 2011;34(2):135-43.
2. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655-79.
3. Schuckit MA. Alcohol-use disorders. Lancet. 2009;373(9662):492-501.
4. Kohn R, Saxena S, Levav I, et al. The treatment gap in mental health care. Bull World Health Organ. 2004;82(11):858-66.
5. National Institute for Health and Clinical Excellence. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence. 2011. http://www.nice.org.uk/nicemedia/live/13337/53191/53191.pdf. Accessed 28 June 2013.
6. Rehm J, Baliunas D, Borges GLG, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction. 2010;105(5):817-43.
7. European Medicines Agency. Selincro (nalmefene): EU summary of product characteristics. 2013. http://www.emea.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002583/WC500140255.pdf. Accessed 28 June 2013.
8. Lundbeck. Lundbeck introduces Selincro® as the first and only medicine for the reduction of alcohol consumption in alcohol dependent patients (media release). 2013. http://files.shareholder.com/downloads/AMDA-GGC00/ 2470573427x0x655042/6278cfbf-543d-49f5-86ad-bc78a2f7d4fe/ Selincro%20First%20Launches.pdf. Accessed 28 June 2013.
9. European Medicines Agency. Selincro (nalmefene): EU assessment report. 2013. http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/002583/WC500140326.pdf. Accessed 28 June 2013.
10. Marinelli PW, Quirion R, Gianoulakis C. A microdialysis profile of β-endorphin and catecholamines in the rat nucleus accumbens following alcohol administration. Psychopharmacology (Berl). 2003;169(1):60-7.
11. Marinelli PW, Quirion R, Gianoulakis C. An in vivo profile of β-endorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol. Neuroscience. 2004;127(3):777-84.
12. Marinelli PW, Bai L, Quirion R, et al. A microdialysis profile of met-enkephalin release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res. 2005;29(10):1821-8.
13. 1-8 release in the rat nucleus accumbens following alcohol administration. Alcohol Clin Exp Res. 2006;30(6):982-90.
14. Gianoulakis C. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. J Psychiatry Neurosci. 2001;26(4):304-18.
15. Walker BM, Koob GF. Pharmacological evidence for a motivational role of κ-opioid systems in ethanol dependence. Neuropsychopharmacology. 2008;33(3):643-52.
16. Modesto-Lowe V, Fritz EM. The opioidergic-alcohol link: implications for treatment. CNS Drugs. 2005;19(8):693-707.
17. Spanagel R, Vengeliene V. New pharmacological treatment strategies for relapse prevention. Curr Top Behav Neurosci. 2013;13:583-609.
18. Przewłocka B, Turchan J, Lasoń W, et al. Ethanol withdrawal enhances the prodynorphin system activity in the rat nucleus accumbens. Neurosci Lett. 1997;238(1-2):13-6.
19. Lindholm S, Ploj K, Franck J, et al. Repeated ethanol administration induces short- and long-term changes in enkephalin and dynorphin tissue concentrations in rat brain. Alcohol. 2000;22(3):165-71.
20. Lindholm S, Rosin A, Dahlin I, et al. Ethanol alters the effect of kappa receptor ligands on dopamine release in the nucleus accumbens. Physiol Behav. 2007;92(1-2):167-71.
21. Nealey KA, Smith AW, Davis SM, et al. κ-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats. Neuropharmacology. 2011;61(1-2):35-42.
22. Kissler JL, Sirohi S, Reis DJ, et al. The one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptors. Biol Psychiatry. 2013. doi: 10.1016/j.biopsych.2013.03.014.
23. Bart G, Schluger JH, Borg L, et al. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology. 2005;30(12):2254-62.
24. France CP, Gerak LR. Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J Pharmacol Exp Ther. 1994;270(3):992-9.
25. Michel ME, Bolger G, Weissman B-A. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol. 1985;7(4):175-7.
26. Ingman K, Hagelberg N, Aalto S, et al. Prolonged central μ-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology. 2005;30(12):2245-53.
27. June HL, Cummings R, Eiler WJA, et al. Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol-preferring (P) rats. Neuropsychopharmacology. 2004;29(2):285-99.
28. June HL, Grey C, Warren-Reese C, et al. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol Clin Exp Res. 1998;22(9):2174-85.
29. Matz J, Graff C, Vainio PJ, et al. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study. Clin Drug Investig. 2011;31(11):799-811.
30. Fudala PJ, Heishman SJ, Henningfield JE, et al. Human pharmacology and abuse potential of nalmefene. Clin Pharmacol Ther. 1991;49(3):300-6.
31. Dixon R, Gentile J, Hsu H-B, et al. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol. 1987;27(3):233-9.
32. Dixon R, Howes J, Gentile J, et al. Nalmefene: intravenous safety and kinetics of a new opioid antagonist. Clin Pharmacol Ther. 1986;39(1):49-53.
33. Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcoho Clin Exp Res. 1994;18(5):1162-7.
34. Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56(8):719-24.
35. Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res. 2007;31(7):1179-87.
36. Anton RF, Pettinati H, Zweben A, et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24(4):421-8.
37. Mann K, Bladström A, Torup L, et al. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry. 2013;73(8):706-13.
38. Gual A, He Y, Torup L, et al. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol. 2013. doi: 10.1016/j.euroneuro. 2013.02.006.
39. van den Brink W, Sørensen P, Torup L, et al. Long-term efficacy, tolerability, and safety of nalmefene as-needed in alcohol-dependence: a randomised, double-blind, placebo-controlled study (abstract no. 0945). Alcohol Clin Exp Res. 2012;36:247 plus poster presented at the 35th Annual Research Society on Alcoholism Scientific Meeting; 23-27 June 2012; San Francisco (CA).
40. World Health Organization. International guide for monitoring alcohol consumption and related harm. 2000. http://whqlibdoc.who.int/hq/2000/WHO-MSD- MSB-00.4.pdf. Accessed 28 June 2013.
41. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. text revision. Washington, DC: American Psychiatric Association; 2000.
42. van den Brink W, Aubin H-J, Baldström A, et al. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol. 2013. doi: 10.1093/alcalc/agt061.
43. Sinclair J, Batel P, Kiefer F, et al. As-needed us of nalmefene in the treatment of alcohol dependence (poster). 21st European Congress of Psychiatry; 6-9 Apr 2013; Nice.
44. van den Brink W, Sørensen P, Torup L, et al. Long-term efficacy of nalmefene as-needed in alcohol dependent patients with high drinking risk levels: results of a subgroup analysis (poster no. 1105). 21st European Congress of Psychiatry; 6-9 Apr 2013; Nice.
45. European Medicines Agency. Guideline on the development of medicinal products for the treatment of alcohol dependence. 2010. http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2010/03/WC500074898.pdf. Accessed 28 June 2013.
46. Gastfriend DR, Garbutt JC, Pettinati HM, et al. Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst Abuse Treat. 2007;33(1):71-80.
47. Marlatt GA, Witkiewitz K. Harm reduction approaches to alcohol use: health promotion, prevention, and treatment. Addict Behav. 2002;27(6):867-86.
48. Marlatt GA, Witkiewitz K. Update on harm-reduction policy and intervention research. Annu Rev Clin Psychol. 2010;6:591-606.
49. Rehm J, Zatonksi W, Taylor B, et al. Epidemiology and alcohol policy in Europe. Addiction. 2011;106(Suppl 1):11-9.
50. Heather N, Adamson SJ, Raistrick D, et al. Initial preference for drinking goal in the treatment of alcohol problems: I. Baseline differences between abstinence and non-abstinence groups. Alcohol Alcohol. 2010;45(2):128-35.
51. Adamson SJ, Heather N, Morton V, et al. Initial preference for drinking goal in the treatment of alcohol problems: II. Treatment outcomes. Alcohol Alcohol. 2010;45(2):136-42.
52. Luquiens A, Reynaud M, Aubin HJ. Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists. Alcohol Alcohol. 2011;46(5):586-91.
53. Biotie Therapies Corp. Selincro launched in the United Kingdom. 2013. http://www.biotie.com/en/investors/stock-exchange-releases/release/?NewsItemID= 1699584&NewsItemYear=2013. Accessed 28 June 2013.
54. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-17.
55. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617-25.
56. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677-85.
57. AOP Orphan Pharmaceuticals AG. Adepend (naltrexone): UK summary of product charactertistics. 2013. http://www.medicines.org.uk/emc/medicine/27620/ SPC/Adepend+50+mg+film-coated+tablets/. Accessed 28 Jun 2013.
58. Actavis UK Ltd. Antabuse tablets (disulfiram): UK summary of product characteristics. 2012. http://www.medicines.org.uk/emc/medicine/519/SPC/ Antabuse+Tablets++200mg/. Accessed 28 June 2013.
59. Merck Serono. Campral EC (acamprosate): UK summary of product characteristics. 2012. http://www.medicines.org.uk/emc/medicine/1042/SPC/ Campral+EC/. Accessed 28 June 2013.
60. Soyka M, Rösner S. Opioid antagonists for pharmacological treatment of alcohol dependence: a critical review. Curr Drug Abuse Rev. 2008;1(3):280-91.
61. Rosner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010(12):CD001867.
62. Theron B, Singhal S. Adverse reactions to drugs used to treat alcoholism. Adverse Drug React Bull. 2007;247:947-50.